Trial reportInflammopharmacology2026
Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions.
Trial report in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04875169 (A Randomized, Double Blind and Placebo Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind and Placebo Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Who cites it
2 citing papers in PubMed.
- From Barrier Disruption and Immune Dysregulation to Targeted Therapies in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveIvarmacitinib (SHR0302) has demonstrated promising efficacy and safety profiles in patients with moderate-to-severe atopic dermatitis (AD). This study aimed to investigate the effects of ivarmacitinib on the extent and severity of moderate-to-severe AD across anatomical regions.
methodsA post-hoc analysis was performed based on the data from a phase III trial of ivarmacitinib (NCT04875169). Patients receiving ivarmacitinib or placebo were included in this study. Eczema Area and Severity Index (EASI) score was assessed in four regions, including the head/neck, upper extremities, trunk, and lower extremities. EASI 75/90/100 response was defined as ≥ 75.0%/90.0%/100.0% improvement in EASI score from baseline.
resultsThere were 112, 113, and 111 patients in the ivarmacitinib 8 mg, ivarmacitinib 4 mg, and placebo groups, respectively. Reductions in EASI scores from baseline for four regions (head/neck, upper extremities, trunk, and lower extremities) were greater in the ivarmacitinib 8 mg and 4 mg groups than in the placebo group at week (W) 1 and sustained until W16. Higher response rates of EASI 100, 90, and 75 across four regions were also observed in ivarmacitinib 8 mg and 4 mg groups versus the placebo group at W4, W8, W12 and W16. Moreover, most of the reductions in EASI erythema, edema/papulation, excoriation, and lichenification scores from baseline to W16 across four regions were greater in the ivarmacitinib 8 mg and 4 mg groups than in the placebo group.
conclusionIvarmacitinib provides rapid and continuous improvement across all anatomical regions in patients with moderate-to-severe AD.
Indexed as
Identifiers
41396379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.